cd38 inhibitor and 5-amino-1mq synergy nad+ The Pharmacology of CD38/NADase: An emerging target for cancer aging diseases SLC25A51 decouples the mitochondrial NAD+/NADH
SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism A Potent and Specific CD38 Inhibitor Ameliorates Age Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline: Cell Metabolism CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions PMC CD38 Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+ Lowering Agents
Pay in 4 interest-free payments of $7.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



